You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Clinical Translation of a Caveolae Targeting Antibody for Enhancing Cancer Drug Delivery

    SBC: Cavatar LLC            Topic: NCI

    PROJECT SUMMARY This proposal aims to develop a novel caveolae targeting antibody for rapid clinical translationIts long term objective is to develop the caveolae pumping systeman active transendothelial transport pathwayto provide an effective solution to the delivery and toxicity problem of systemically administered chemotoxinsWork will be based on the current proprietary mouse monoclonal antibo ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD

    SBC: ONL Therapeutics, Inc.            Topic: NEI

    PROJECT SUMMARYABSTRACT Age related macular degenerationAMDis the leadingand due to the aging baby boomersa growing cause of irreversible vision loss in the United Statesand is strongly associated with exposure to cigarette smokeCSand high fat dietsHFDWhile effective treatment is available for neovascular AMDthe AREDS II antioxidant vitamins are the only proven treatment for intermediate dry AMDUn ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. O-Glycan-dependent Immunotherapy for Cancer

    SBC: GLYTR THERAPEUTICS, INC.            Topic: 102

    Abstract For decadesthe treatment of cancer has relied on surgical resectionchemotherapy and or radiotherapyRecentlya number of immune based therapies have provided promising new approaches for cancer treatmentThe two most potent immunotherapies are monoclonal antibodymABbased bi specific proteinseg Bispecific T cell engagersBiTEand engineered Chimeric Antigen Receptor T cellsCAR TBoth act by indu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100

    SBC: NEONC TECHNOLOGIES INC            Topic: 102

    Project Summary Abstract Many pharmaceutical agents are highly potentbut are unable to exert substantial therapeutic activity against disorders of the brainbecause the blood brain barrierBBBeffectively prevents their access to the site of intracerebral diseaseFor examplethe majority of glioblastoma patientsdespite the best efforts of current medical caredie within two years after diagnosisHencethe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Poloxamer 188 mechanism of action in ischemic heart failure.

    SBC: PHRIXUS PHARMACEUTICALS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): This project was initiated to determine how Poloxamer-188 (P-188) improves cardiac function in ischemic heart failure (HF). While it is accepted that lack of oxygen (ischemia) results in tissue damage, the direct involvement of membrane injury in the progression of ischemic HF is a relatively novel concept. The long-term goal of this project is to establish a r ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. C/EBP-beta PEPTIDES FOR THE TREATMENT OF LIVER INJURY AND FIBROSIS

    SBC: XFIBRA, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Activation of hepatic stellate cells (HSC) is responsible for the development of liver fibrosis in chronic liver diseases of all causes and remarkably, HSC clearance by apoptosis may allow recovery from liver injury andreversal of liver fibrosis. There is full agreement among liver fibrosis experts that inhibiting o reversing HS activation (the therapeutic targ ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Small Molecule targeting of NADPH oxidase in neutrophils

    SBC: P2D, INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are characterized by a rapid and severe respiratory failure, arising after clinical events including major surgery, trauma, multiple transfusions and sepsis. ALI/ARDS have an associated mortality of 40-80% and current pharmacological modalities have been unsuccessful in decreasing mortality. ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice

    SBC: Yecuris Corporation            Topic: NCRR

    DESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Pulse Oximeter for Newborn Screening

    SBC: INTELLIGENT OPTICAL SYSTEMS, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): Congenital heart diseases (CHD) are the most common serious congenital anomalies and the leading cause of death due to birth defects. Clinical practice relying on physical examination of the newborn before discharge from the nursery often misses newborns with critical CHD (CCHD), which can lead to death or long-term morbidities. Using pulse oximetry (PO) can im ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Automatic Insulin Dosage Adjustment to Improve Glycemic Control of Diabetic Patie

    SBC: HYGIEIA RESEARCH, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Diabetes has become a growing epidemic, yet treatment goals are seldom achieved, and patients endure detrimental complications. Insulin is the only dose-dependent antidiabetic medication in which most patients can accomplish balanced blood glucose levels when adequate dosages are prescribed. Nonetheless, only when insulin dosage is frequently titrated, is the f ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government